Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 8/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.43 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.43 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22138851 | 0.94 | DNM1 (0.47) | DNM1LPAR1LPAR3LPAR2LPAR6 | |
| SCHEMBL26578211 | 0.94 | DNM1 (0.42) | DNM1LPAR1LPAR3LPAR2LPAR6 | |
| SCHEMBL114432 | 0.92 | DNM1 (0.57) | DNM1LPAR1LPAR3LPAR2LPAR6 | |
| SCHEMBL26577995 | 0.90 | DNM1 (0.45) | DNM1LPAR1LPAR3LPAR2LPAR6 | |
| SCHEMBL22654529 | 0.88 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2LPAR6 | |
| SCHEMBL22654528 | 0.88 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2LPAR6 | |
| SCHEMBL17263911 | 0.88 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2LPAR6 | |
| SCHEMBL5532689 | 0.88 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2LPAR6 | |
| SCHEMBL11181978 | 0.88 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2LPAR6 | |
| SCHEMBL11189857 | 0.88 | DNM1 (0.61) | DNM1LPAR1LPAR3LPAR2LPAR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230557-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | DNM1 785/4885LPAR1 3338/4885LPAR3 3097/4885 |
| US-11230557-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | DNM1 785/4885LPAR1 3338/4885LPAR3 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.